References:
- Ari Pelcovits and Rabin N. Acute Myeloid Leukemia: A Review.Rhode Island medical journal (2013). 2020;103.
- Toshiya Inaba and Akiko N. Monosomy 7: recent progress .[Rinsho ketsueki] The Japanese journal of clinical
hematology. 2019;60:1020-1026 , pmid = 31597823.
- Berger LBaABaGLaGSaR. Monosomy-7 in childhood hemopoietic disorders.Leukemia. 1990;4:345-349 , pmid = 2201828.
- Marcin WWaSSSaCMN. Monosomy 7 in Pediatric Myelodysplastic Syndromes.Hematology/oncology clinics of North America. 2018;32:729-743 ,
pmid = 30047423 , publisher = Hematol Oncol Clin North Am.
- Tathagata Chatterjee and VPC. Childhood Myelodysplastic Syndrome ,.Symposium on Pediatric Oncology: Hemato-Oncology.
- Makia KMaTAHaARLaRERaQLaSNFaSM. Functional Consequence and Therapeutic
Targeting of Cryptic ALK Fusions (ALK fus) in Monosomy7 AML.Blood. 2021;138:2357 , publisher = Content Repository Only!
- Palmer BHaRH. The role of the ALK receptor in cancer biology.Annals of Oncology. 2016;27.
- Cao Z, Gao Q, Fu M, Ni N, Pei Y, Ou WB. Anaplastic lymphoma kinase
fusions: Roles in cancer and therapeutic perspectives (Review).Oncology Letters. 2018.
- Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
ALK inhibitors in the treatment of advance NSCLC. In: Elsevier
Health 2013.
- Javier, Molina-Cerrillo JE-VaJJS-CaJPaMSR-GaIO-MaJT-JaACaTA-G.
Tyrosine kinase receptors in oncology. International Journal of
Molecular Sciences. 2020;21.
- Xue Du and Yun Shao and Hai Feng Qin and Yan Hong Tai and Hong Jun G.
ALK-rearrangement in non-small-cell lung cancer (NSCLC).Thoracic Cancer. 2018;9.
- Kayo Takeoka and Atsuko Okumura and Yoshitomo Maesako and Takashi
Akasaka and Hitoshi O. Crizotinib resistance in acute myeloid leukemia
with inv(2)(p23q13)/RAN binding protein 2 (RANBP2) anaplastic lymphoma
kinase (ALK) fusion and monosomy 7. Cancer Genetics. 2015;208.
- Fei Fei Gu and Yong Zhang and Yang Yang Liu and Xiao Hua Hong and Jin
Yan Liang and Fan Tong and Jing Song Yang and Li L. Lung
adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met
overexpression, and HER-2 amplification with inherent resistance to
crizotinib, chemotherapy, and radiotherapy. Journal of
Hematology and Oncology. 2016;9.
- Liu W, Duan Q, Gong L, et al. A novel LRRFIP1-ALK fusion in
inflammatory myofibroblastic tumor of hip and response to crizotinib.Investigational New Drugs. 2021;39(1):278-282.
- Jin L, Wang Y, Li S, Chen D, Zhao X. Novel PNPT1-ALK fusion variant
exerted significant benefit to crizotinib in NSCLC. Lung
Cancer. 2020;146:382-384.
- Yao Chen and Xiaochen Zhang and Qi Jiang and Bo Wang and Yina Wang and
Yan J. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to
crizotinib. Lung Cancer. 2020;146:370-372.
- Mossé YP, Voss SD, Lim MS, et al. Targeting ALK With Crizotinib in
Pediatric Anaplastic Large Cell Lymphoma and Inflammatory
Myofibroblastic Tumor: A Children’s Oncology Group Study.Journal of Clinical Oncology. 2017;35(28):3215-3221.
- Felkai L, Bánusz R, Kovalszky I, et al. The Presence of ALK
Alterations and Clinical Relevance of Crizotinib Treatment in
Pediatric Solid Tumors. Pathology & Oncology Research.2019;25(1):217-224.
- Yael PMaSDVaMSLaDRaCGMaEFaPAaKWaS. Targeting ALK with crizotinib in
pediatric anaplastic large cell lymphoma and inflammatory
myofibroblastic tumor: A Children’s Oncology Group study.Journal of Clinical Oncology. 2017;35.
- Katherine Tarlock and Todd AAaYCWaRBGaRRaMRLaLPaTHaJJ. Functional
properties of KIT mutations are associated with differential clinical
outcomes and response to targeted therapeutics in CBF acute myeloid
leukemia. Clinical Cancer Research. 2019;25.